ARKG
ETF
Genomics
NYSEARCA
ARK Genomic Revolution ETF
$40.27
-0.99 (-2.40%)
Fund Overview
by ARK Invest
Actively managed fund focused on the genomic revolution: gene editing (CRISPR), molecular diagnostics, targeted therapeutics, stem cells, and agricultural biology. High-conviction positions in companies reshaping medicine.
AUM$1.8B
Expense Ratio0.75%
Holdings35
Dividend Yield0.0%
DistributionAnnually
BenchmarkNone (Active)
InceptionOct 2014
ExchangeNYSEARCA
Price Data
Open$41.95
Prev Close$41.26
Day Range$39.96 — $42.63
52W Range$17.55 — $34.37
52-Week Range
$17.55
$34.37
From 52W High
17.2%
From 52W Low
+129.5%
Genomics ETF Comparison
Top Genomics Stocks
View all →
| Stock | Price | Change | Market Cap |
|---|---|---|---|
| ABBV | $283.54 | -0.86% | 520.47B |
| AMGN | $438.82 | -1.14% | 252.64B |
| GILD | $166.53 | -1.45% | 208.95B |
| VRTX | $520.66 | -2.94% | 134.82B |
| REGN | $923.34 | -2.35% | 98.38B |
| MRNA | $199.33 | +1.29% | 90.54B |
| NTRA | $289.92 | +0.15% | 45.90B |
| RVMD | $159.43 | -0.24% | 37.37B |
| BIIB | $247.13 | -1.70% | 37.21B |
| ROIV | $38.96 | +0.59% | 28.64B |
ARKG FAQ
What is ARKG?
ARKG is the ARK Genomic Revolution ETF, an exchange-traded fund managed by ARK Invest. It tracks the None (Active) and holds 35 Genomics securities with an expense ratio of 0.75%.
What is the expense ratio of ARKG?
ARKG charges an annual expense ratio of 0.75%, which means you pay $75.00 per year for every $10,000 invested. This fee is deducted automatically from the fund's returns.
Explore Genomics Stocks
View our full list of individual genomics stocks with prices, fundamentals, and analyst ratings.
Last updated: Nov 19, 2026 at 10:42 PM ET